Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Surmodics, Inc. (SRDX : NSDQ)
 
 • Company Description   
Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports through two divisions: Medical Devices & IVD.?The Medical Devices segment comprises surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others. The IVD segment includes component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

Number of Employees: 447

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.23 Daily Weekly Monthly
20 Day Moving Average: 80,437 shares
Shares Outstanding: 14.13 (millions)
Market Capitalization: $257.64 (millions)
Beta: 1.00
52 Week High: $39.99
52 Week Low: $16.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.30% -19.47%
12 Week -6.56% -13.26%
Year To Date -46.57% -51.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9924 WEST 74TH STREET
-
EDEN PRAIRIE,MN 55344
USA
ph: 952-500-7000
fax: 952-500-7001
ir@surmodics.com http://www.surmodics.com
 
 • General Corporate Information   
Officers
Gary R. Maharaj - President and Chief Executive Officer
Timothy J. Arens - Senior Vice President of Finance and Vice Presiden
Jose H. Bedoya - Director
David R. Dantzker - Director
Ronald B. Kalich - Director

Peer Information
Surmodics, Inc. (BJCT)
Surmodics, Inc. (CADMQ)
Surmodics, Inc. (APNO)
Surmodics, Inc. (UPDC)
Surmodics, Inc. (IMTIQ)
Surmodics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 868873100
SIC: 3841
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 07/26/23
Share - Related Items
Shares Outstanding: 14.13
Most Recent Split Date: 12.00 (2.00:1)
Beta: 1.00
Market Capitalization: $257.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.85 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/26/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.51
Price/Cash Flow: -
Price / Sales: 2.50
EPS Growth
vs. Year Ago Period: -81.82%
vs. Previous Quarter: 20.00%
Sales Growth
vs. Year Ago Period: 4.18%
vs. Previous Quarter: 9.08%
ROE
03/31/23 - -18.98
12/31/22 - -15.61
09/30/22 - -10.59
ROA
03/31/23 - -12.56
12/31/22 - -10.75
09/30/22 - -7.58
Current Ratio
03/31/23 - 3.20
12/31/22 - 3.73
09/30/22 - 1.80
Quick Ratio
03/31/23 - 2.48
12/31/22 - 3.00
09/30/22 - 1.43
Operating Margin
03/31/23 - -20.43
12/31/22 - -18.15
09/30/22 - -13.33
Net Margin
03/31/23 - -34.92
12/31/22 - -31.71
09/30/22 - -27.29
Pre-Tax Margin
03/31/23 - -28.50
12/31/22 - -26.49
09/30/22 - -22.50
Book Value
03/31/23 - 7.26
12/31/22 - 7.59
09/30/22 - 7.75
Inventory Turnover
03/31/23 - 1.77
12/31/22 - 1.88
09/30/22 - 2.01
Debt-to-Equity
03/31/23 - 0.29
12/31/22 - 0.27
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 22.22
12/31/22 - 21.57
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©